Outpatient treatment of confirmed COVID-19: living, rapid practice points from the American College of Physicians (version 1)
A Qaseem, J Yost, MC Miller, R Andrews… - Annals of Internal …, 2023 - acpjournals.org
An updated version of this article was published on 19 September 2023. Description:
Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data …
Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data …
Therapeutic role of neutralizing antibody for the treatment against SARS-CoV-2 and its emerging variants: A clinical and pre-clinical perspective
Since early 2020, the entire world has been facing a disastrous outbreak of the SARS-CoV-2
virus, with massive reporting of death and infections per day. Medical practitioners adopted …
virus, with massive reporting of death and infections per day. Medical practitioners adopted …
A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
X Wang, A Hu, X Chen, Y Zhang, F Yu, S Yue… - … and Targeted Therapy, 2022 - nature.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal …
pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal …
A randomized clinical trial of regdanvimab in high-risk patients with mild-to-moderate coronavirus disease 2019
JY Kim, O Săndulescu, LL Preotescu… - Open forum …, 2022 - academic.oup.com
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
Therapeutic developments for SARS-CoV-2 infection—molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in …
O Săndulescu, CG Apostolescu… - Frontiers in …, 2023 - frontiersin.org
This article systematically presents the current clinically significant therapeutic
developments for the treatment of COVID-19 by providing an in-depth review of molecular …
developments for the treatment of COVID-19 by providing an in-depth review of molecular …
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
S Iketani, DD Ho - Cell Chemical Biology, 2024 - cell.com
Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
[HTML][HTML] Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS …
CT-P59, a monoclonal antibody with potent neutralizing activity against severe acute
respiratory syndrome coronavirus 2, may ameliorate symptoms and prevent hospitalization …
respiratory syndrome coronavirus 2, may ameliorate symptoms and prevent hospitalization …
[HTML][HTML] Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: a propensity score–matched retrospective cohort study
S Lee, SO Lee, JE Lee, KH Kim, SH Lee… - International …, 2022 - Elsevier
Abstract Background Regdanvimab (CT-P59) is a neutralizing antibody authorized in
Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who …
Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who …
[HTML][HTML] Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation
The identification of the SARS-CoV-2 Omicron variants BA. 4/BA. 5, BF. 7 and BQ. 1.1
immediately raised concerns regarding the efficacy of currently used monoclonal antibody …
immediately raised concerns regarding the efficacy of currently used monoclonal antibody …
Real-world efficacy of regdanvimab on clinical outcomes in patients with mild to moderate COVID-19
T Kim, DH Joo, SW Lee, J Lee, SJ Lee… - Journal of Clinical …, 2022 - mdpi.com
Background: This study aims to evaluate the real-world effectiveness of regdanvimab on
clinical outcomes in patients with mild to moderate coronavirus disease 2019 (COVID-19) …
clinical outcomes in patients with mild to moderate coronavirus disease 2019 (COVID-19) …